A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma

Overview of attention for article published in Experimental Hematology & Oncology, February 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (62nd percentile)
Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

twitter: 5 X users

Readers on

mendeley: 3 Mendeley

Summary X

So far, Altmetric has seen 9 X posts from 5 X users, with an upper bound of 7,822 followers.

A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma #lymphoma #lymsm https://t.co/QUV7UaWVO3

28 Feb 2022

Reply Repost Favourite

27 Feb 2022

Reply Repost Favourite

RT @Lymphoma_Papers: A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients wit…

26 Feb 2022

Reply Repost Favourite

RT @Lymphoma_Papers: A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients wit…

26 Feb 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.